Ludwig Boltzmann Institute for Experimental and Clinical Traumatology in AUVA research centre Vienna, Austria.
Front Physiol. 2013 May 20;4:101. doi: 10.3389/fphys.2013.00101. eCollection 2013.
Apart from ATP synthesis mitochondria have many other functions, one being nitrite reductase activity. Nitric oxide (NO) released from nitrite has been shown to protect the heart from ischemia/reperfusion (I/R) injury in a cGMP-dependent manner. However, the exact impact of mitochondria on the release of NO from nitrite in cardiomyocytes is not completely understood. Besides mitochondria, a number of non-mitochondrial metalloproteins have been suggested to facilitate this process. The aim of this study was to investigate the impact of mitochondria on the bioactivation of nitrite in HL-1 cardiomyocytes. The levels of nitrosyl complexes of hemoglobin (NO-Hb) and cGMP levels were measured by electron spin resonance spectroscopy and enzyme immunoassay. In addition the formation of free NO was determined by confocal microscopy as well as intracellular nitrite and S-nitrosothiols by chemoluminescence analysis. NO was released from nitrite in cell culture in an oxygen-dependent manner. Application of specific inhibitors of the respiratory chain, p450, NO synthases (NOS) and xanthine oxidoreductase (XOR) showed that all four enzymatic systems are involved in the release of NO, but more than 50% of NO is released via the mitochondrial pathway. Only NO released by mitochondria activated cGMP synthesis. Cardiomyocytes co-cultured with red blood cells (RBC) competed with RBC for nitrite, but free NO was detected only in HL-1 cells suggesting that RBC are not a source of NO in this model. Apart from activation of cGMP synthesis, NO formed in HL-1 cells diffused out of the cells and formed NO-Hb complexes. In addition nitrite was converted by HL-1 cells to S-nitrosyl complexes. In HL-1 cardiomyocytes, several enzymatic systems are involved in nitrite reduction to NO but only the mitochondrial pathway of NO release activates cGMP synthesis. Our data suggest that this pathway may be a key regulator of myocardial contractility especially under hypoxic conditions.
除了 ATP 合成外,线粒体还有许多其他功能,其中之一是亚硝酸盐还原酶活性。已经表明,从亚硝酸盐释放的一氧化氮 (NO) 以 cGMP 依赖性方式保护心脏免受缺血/再灌注 (I/R) 损伤。然而,线粒体对心肌细胞中亚硝酸盐释放 NO 的具体影响尚不完全清楚。除了线粒体,许多非线粒体金属蛋白酶已被认为有助于这一过程。本研究旨在研究线粒体对 HL-1 心肌细胞中亚硝酸盐生物活化的影响。通过电子自旋共振光谱和酶免疫测定法测量血红蛋白的亚硝酰复合物 (NO-Hb) 和 cGMP 水平。此外,通过共聚焦显微镜测定游离 NO 的形成以及细胞内亚硝酸盐和 S-亚硝基硫醇通过化学发光分析。NO 以依赖于氧的方式从亚硝酸盐在细胞培养物中释放。应用呼吸链、细胞色素 P450、一氧化氮合酶 (NOS) 和黄嘌呤氧化还原酶 (XOR) 的特异性抑制剂表明,所有四种酶系统都参与了 NO 的释放,但超过 50%的 NO 通过线粒体途径释放。只有通过线粒体释放的 NO 才能激活 cGMP 合成。与红细胞 (RBC) 共培养的心肌细胞与 RBC 竞争亚硝酸盐,但仅在 HL-1 细胞中检测到游离 NO,这表明在该模型中 RBC 不是 NO 的来源。除了激活 cGMP 合成外,HL-1 细胞中形成的 NO 扩散出细胞并形成 NO-Hb 复合物。此外,HL-1 细胞将亚硝酸盐转化为 S-亚硝酰复合物。在 HL-1 心肌细胞中,几种酶系统参与亚硝酸盐还原为 NO,但只有 NO 释放的线粒体途径才能激活 cGMP 合成。我们的数据表明,该途径可能是心肌收缩性的关键调节剂,尤其是在缺氧条件下。